10.6084/m9.figshare.3980160.v1
Akane Yamamichi
Akane
Yamamichi
Toshihiro Kasama
Toshihiro
Kasama
Fumiharu Ohka
Fumiharu
Ohka
Hiromichi Suzuki
Hiromichi
Suzuki
Akira Kato
Akira
Kato
Kazuya Motomura
Kazuya
Motomura
Masaki Hirano
Masaki
Hirano
Melissa Ranjit
Melissa
Ranjit
Lushun Chalise
Lushun
Chalise
Michihiro Kurimoto
Michihiro
Kurimoto
Goro Kondo
Goro
Kondo
Kosuke Aoki
Kosuke
Aoki
Noritada Kaji
Noritada
Kaji
Manabu Tokeshi
Manabu
Tokeshi
Toshio Matsubara
Toshio
Matsubara
Takeshi Senga
Takeshi
Senga
Mika K. Kaneko
Mika K.
Kaneko
Hidenori Suzuki
Hidenori
Suzuki
Masahito Hara
Masahito
Hara
Toshihiko Wakabayashi
Toshihiko
Wakabayashi
Yoshinobu Baba
Yoshinobu
Baba
Yukinari Kato
Yukinari
Kato
Atsushi Natsume
Atsushi
Natsume
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas
Taylor & Francis Group
2016
Glioma
isocitrate dehydrogenase 1 mutation
immuno-wall microdevice
rapid diagnosis
precision medicine
30 Bio-inspired and biomedical materials
404 Materials informatics / Genomics
2016-10-04 10:51:07
Dataset
https://tandf.figshare.com/articles/dataset/An_immuno-wall_microdevice_exhibits_rapid_and_sensitive_detection_of_IDH1-R132H_mutation_specific_to_grade_II_and_III_gliomas/3980160
<p>World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (<i>IDH1</i>), of which 83–90% are found to be the <i>IDH1-R132H</i> mutation. Detection of the <i>IDH1-R132H</i> mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the <i>IDH1-R132H</i> mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the <i>IDH1</i> status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the <i>IDH1-R132H</i> mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the <i>IDH1-R132H</i> mutation in routine clinical practice.</p>